Phase 2 N=43 Lovaza's Effect on the Activation of Platelets
Cardiovascular Disease · Bleeding
Primary: Platelet Aggegation (Arachiodonic Acid)Using a PAP-8E (BioData Corp.) — 79.5; 0; 5.5; 8 percent
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=101 Topical Tranexamic Acid and Acute Blood Loss in Total Knee Arthroplasty
Acute Blood Loss Anemia · Osteoarthritis, Knee
Primary: Blood Loss — 1293.1; 940.2 mL
Phase 2 N=59 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Phase 2 N=82 Rituximab and ABVD for Hodgkin's Patients
Lymphoma
Primary: 5-year Failure-free Survival Rate for Participants With Hodgkin's Disease Given Rituximab With ABVD — 83 percentage of participants
Phase 2 N=101 A Comfort Study of Brinzolamide 1% / Brimonidine 0.2% Fixed Combination, Brinzolamide 1% and Brimonidine 0.2%
Open-Angle Glaucoma · Ocular Hypertension
Primary: Mean Ocular Discomfort Score — 0.8; 0.4; 0.3 Units on a scale
Phase 2 N=34 Alteration in Timing of Plerixafor Administration
Autologous Transplantation
Primary: Number of Patients Who Collected ≥ 6 x 10^6 CD34+ Cells by Day 5 (4 Apheresis Sessions) With Plerixafor Administration at 1500. — 31 Participants
Phase 2 N=40 Free Fatty Acids and Vascular Function in Subjects With Diabetes
Type 2 Diabetes Mellitus
Primary: Flow-mediated Dilation After Placebo or Acipimox Treatment Between Healthy Controls and Those With Metabolic Syndrome — 10.65; 11.57; 8.79; 9.52 Flow mediated dilation
Phase 2 N=12 Sleep Apnea Treatment With Expiratory Resistance(Provent™)
Sleep Apnea, Obstructive
Primary: Change in AHI — 45; -15.8 events/h
Phase 2 N=340 Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants
Malaria · Malaria Vaccines
Primary: Concentrations of Antibodies Against Hepatitis B (Anti-HB) — 13.0; 14.3; 16.9; 111.8 milli-international unit per milliliter
Phase 2 N=61 A Study to Evaluate the Effectiveness of Infliximab and Changes in Hand and Wrist Magnetic Resonance Imaging (MRI) in Participants With Active Rheumatoid Arthritis (RA) (P08136)
Arthritis, Rheumatoid
Primary: Change From Baseline in the Volume Transfer Rate From the Blood Plasma to the Enhancing Synovium (Ktrans) — -0.2; 0.1 min ^-1 — p=<0.001
Phase 2 N=24 S-Adenosyl Methionine (SAMe) to Treat Patients With Chronic Hepatitis C
Chronic Hepatitis C
Primary: Improvement in Viral Kinetics During the First 2 Weeks of Therapy — 14 participants
Phase 2 N=83 Exploration of Safety and Efficacy of AzA 15% Foam Twice a Day in Rosacea
Papulopustular Rosacea
Primary: Nominal Change From Baseline in Inflammatory Lesion (IL) Count (Sum of Papules and Pustules) Per Participant at End of Study (LOCF: Last Observation Carried Forward)…
Phase 2 N=41 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia
Adult Acute Basophilic Leukemia · Adult Acute Eosinophilic Leukemia · Adult Acute Megakaryoblastic Leukemia (M7)
Primary: Complete Response — 11 percentage of participants
Phase 2 N=59 Study of SyB L-0501 in Combination With Rituximab to Treat Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Non-Hodgkin's Lymphoma · Lymphoma, Large Cell · Diffuse, Mantle Cell Lymphoma, Lymphoma
Primary: The Overall Response Rate [Complete Response (CR) + Partial Response (PR)] Determined on the Basis of Revised Response Criteria for Malignant Lymphoma — 62.7 Percentage…
Phase 2 N=30 Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
Squamous Cell Carcinoma of Head and Neck
Primary: Partial Response Rate in Both Groups of Patients. — 7; 13 percentage of participants